Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells.

@article{Rossier1998InhibitoryAO,
  title={Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells.},
  author={Michel Florian Rossier and Eric A. Ertel and Michel B. Vallotton and Alessandro M Capponi},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1998},
  volume={287 3},
  pages={824-31}
}
Mibefradil is a new cardiovascular drug with peculiar Ca++ antagonistic properties. The most remarkable feature of mibefradil is its unique relative selectivity for T type calcium channels, a property that has been proposed to explain in part the beneficial pharmacological and clinical profiles of this drug. In adrenal glomerulosa cells, aldosterone biosynthesis and secretion in response to angiotensin II or extracellular potassium is dependent on a sustained influx of Ca++ through T type Ca… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Block of cardiac calcium channels by the new calcium antagonist Ro 405967 : Consequences on heart rate and cardiac output

  • M Mangoni, V Leuranguer, E Bourinet, Nargeot JSR
  • Biophys J
  • 1997
1 Excerpt

Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil

  • B Cremers, M Flesch, M Sudkamp, M Bohm
  • J Cardiovasc Pharmacol
  • 1997
2 Excerpts

Similar Papers

Loading similar papers…